Welcome to our dedicated page for Arcadia Bioscien SEC filings (Ticker: RKDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arcadia Biosciences, Inc. filings document the company's plant-based products business, operating results, governance matters, and capital structure. Its 8-K reports cover material agreements, inducement transactions involving preferred investment options and common stock, shareholder voting matters, board changes, and changes in the company's independent registered public accounting firm.
Arcadia's proxy and periodic disclosures address executive compensation, board governance, internal control over financial reporting, going-concern risk language, and other risks associated with recurring losses, cash use, financing needs, and public-company compliance.
Arcadia Biosciences entered into and closed a $4 million private placement of pre-funded warrants and preferred investment options with an institutional accredited investor, priced at-the-market under Nasdaq rules. The investor purchased pre-funded warrants and Series A-1 and A-2 preferred investment options linked to up to 3,883,496 shares of common stock each, at a purchase price of about $1.03 per unit. The pre-funded warrants are immediately exercisable at $0.0001 per share with no expiration until fully exercised, while the Series A-1 and A-2 options carry a $0.91 exercise price with five-year and two-year terms, respectively, subject to stockholder approval and registration timing. Arcadia agreed to file resale registration statements, observe issuance restrictions and potential cashless exercise features, and granted H.C. Wainwright placement fees, expense reimbursements, and 271,845 placement agent options. Net proceeds are earmarked for working capital and general corporate purposes.
Arcadia Biosciences, Inc. reporting persons Armistice Capital, LLC and Steven Boyd beneficially own 159,390 shares of Common Stock, representing 7.75% of the class. The filing states shared voting and dispositive power over the 159,390 shares and is signed May 15, 2026.
Arcadia Biosciences reported a sharp swing to loss in the quarter ended March 31, 2026, alongside serious liquidity pressure and a going concern warning. Product revenue from Zola coconut water was $1.1 million, down 8% from $1.2 million a year earlier, mainly because a prior-year revenue reserve release did not recur.
The company posted a net loss attributable to common stockholders of $4.4 million, versus net income of $2.6 million in the prior-year quarter. Results were heavily affected by a $2.9 million Loss on January 2026 Inducement Offer tied to modified warrants and options, and a $1.5 million unrealized loss on AFII shares received from the GoodWheat sale. These were partly offset by a $1.2 million non‑cash gain from remeasuring warrant and option liabilities.
Cash and cash equivalents were $1.0 million as of March 31, 2026, with working capital of $3.8 million. Management states this cash will not cover anticipated needs for at least 12 months, leading to substantial doubt about the company’s ability to continue as a going concern. Above Food’s default on a $4.0 million remaining promissory note and uncertainty around monetizing AFII shares further strain funding, and Arcadia may need additional equity, debt, asset sales, or strategic alternatives to continue operating.
Arcadia Biosciences reported first-quarter 2026 results showing growth in its Zola coconut water brand but a sharp swing back to losses. Product revenues were $1.1 million, down 8% from $1.2 million a year earlier, mainly because 2025 benefited from a one-time revenue reserve release.
Total operating expenses rose to $1.9 million from $670,000, as the prior year included a $750,000 gain on sale of patent portfolios and a $1.0 million gain from a change in contingent consideration. The company posted a net loss attributable to common stockholders of $4.4 million, or $2.11 per share, compared with net income of $2.6 million, or $1.90 per share, in the first quarter of 2025.
Management highlighted that Zola volumes increased 18% and that selling, general and administrative expenses were at their lowest level in the company’s public history. Arcadia ended March 31, 2026 with cash of $954,000 and short-term investments of $2.8 million, supported by approximately $2.1 million of gross proceeds from exercises of preferred investment options and $2.1 million from a January 2026 warrant inducement offer. The company cautioned it will require additional funding in the near future to continue operations and planned activities.
Arcadia Biosciences, Inc. filed an amendment to its 2025 annual report to add the required Part III information on directors, executive compensation, security ownership, related-party transactions, and auditor fees, without updating prior financial results.
The filing details the board and committee structure, independence determinations, and compensation for executives and non-employee directors, including option grants and severance and change in control agreements. It also describes expired equity plans and a January 2026 inducement transaction in which major holders exercised preferred investment options for cash proceeds of about $2.1 million and received new preferred investment options.
Arcadia Biosciences, Inc. filed an 8‑K announcing that its audit committee dismissed Deloitte & Touche as independent auditor and appointed Ramirez Jimenez International CPAs (RJI), effective March 30, 2026. Deloitte’s reports on the 2024 and 2025 financial statements included an explanatory paragraph about the company’s ability to continue as a going concern, citing accumulated deficit, recurring net losses, net cash used in operations and limited resources.
The company also reiterates previously disclosed material weaknesses in internal control over financial reporting, including insufficient segregation of duties in the financial close process and insufficient information system controls such as access and change management, driven in part by reduced employee headcount. The 8‑K states there were no disagreements with Deloitte on accounting principles, disclosure, or audit scope, and that Deloitte has been authorized to respond fully to RJI’s inquiries. A confirming letter from Deloitte to the SEC is attached as an exhibit.
Arcadia Biosciences, Inc. reports 2025 product revenue of $4.9M, down slightly as GLA oil sales ended, while Zola coconut water revenue rose 17%. Net loss from continuing operations narrowed to $2.3M from $4.3M in 2024 as operating expenses declined.
The company recorded a $4.7M credit loss after Above Food defaulted on a promissory note from the 2024 GoodWheat sale, partially offset by a $2.0M gain from reducing contingent consideration and a $2.3M gain on AFII stock. Cash and cash equivalents were $0.3M at year-end, and auditors highlighted substantial doubt about Arcadia’s ability to continue as a going concern.
Arcadia has exited wheat trait commercialization and GoodWheat, now focusing on Zola coconut water sourced from Thailand amid evolving U.S. tariff policy. The Roosevelt Resources all-stock combination was terminated with no expected break-up fee, and the company faces a Proposition 65 lawsuit over BPA in canned coconut water and stockholder demand letters related to the terminated Roosevelt transaction.
Arcadia Biosciences reported smaller losses for 2025 but faces liquidity pressure. Total revenues were $4.9M, down slightly from $5.0M, while Zola® coconut water revenues grew 17% year over year. Selling, general and administrative costs fell about 27%, helping reduce net loss attributable to common stockholders to $2.3M from $7.0M.
Cash and cash equivalents dropped to $259K as of December 31, 2025, from $4.2M a year earlier. A proposed business combination with Roosevelt Resources was terminated, and the company raised approximately $2.1M in gross proceeds from the exercise of preferred investment options. Management states it will require additional funding in the near future and may pursue equity or debt financings or asset transactions, which could dilute existing shareholders.
Arcadia Biosciences, Inc. is registering for resale up to 1,673,792 shares of common stock, issuable upon exercise of preferred investment options held by existing investors and placement agents. This includes up to 1,617,190 shares from new Investment Options and 56,602 shares from Placement Agent Options.
The company will not receive proceeds from stockholder resales, but could receive up to approximately $3.94 million if all options are exercised for cash, which it plans to use for working capital and general corporate purposes. Common stock outstanding was 1,729,884 shares as of January 23, 2026, and would be 3,403,676 shares assuming full cash exercise of the Options. Arcadia now focuses on its Zola coconut water brand after selling several legacy crop-related assets, and discloses substantial doubt about its ability to continue as a going concern without additional financing. A previously planned all-stock business combination with Roosevelt Resources, LP has been terminated.
Arcadia Biosciences, Inc. reported that two members of its board of directors, Albert D. Bolles, Ph.D. and Deborah Carosella, resigned from the board effective February 4, 2026.
Bolles served on the Compensation Committee, while Carosella served on both the Compensation Committee and the Nominating and Governance Committee. The company stated that their resignations were not due to any disagreement with the company or its board regarding operations, policies, practices, or financial statements. Both former directors agreed to remain available to assist the company in an advisory capacity.